Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy

Lu, Qianyi; Lu, Li; Chen, Bin; Chen, Wei; Lu, Peirong

doi:10.1016/j.jcjo.2018.06.010

Cited by 10 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have shown that vascular endothelial growth factor (VEGF) participates in retinal neovascularization. 14 Intravitreal injection of anti-VEGF drugs has become an adjuvant therapy before vitrectomy. 15,16 Conbercept (KH902; Chengdu Kanghong Biotechnology Co., Ltd., Sichuan, China), a new anti-VEGF reagent, has been developed and used in clinical treatment.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

Wang

Pengfei

Liu³

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objective: This study assessed the efficacy of conbercept for patients with non-proliferative diabetic retinopathy (NPDR). Methods: In this retrospective clinical study, 54 patients with NPDR (54 eyes) were treated with intravitreal injection of conbercept using a 3þ pro re nata regimen and followed up for 12 months. Best corrected visual acuity (BCVA), central foveal thickness (CFT), area of hard exudate (HE), and number of microaneurysms (MAs) were used as indicators of therapeutic effects. Systemic adverse reactions were recorded to assess safety. Results: During the 12-month follow-up period, the mean number of injections was 6.12 AE 1.89 on demand. From baseline to the 12-month follow-up, the BCVA of patients with NPDR increased from 0.71 AE 0.20 logMAR to 0.43 AE 0.16 logMAR, CFT decreased from 424.26

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

Wang

Pengfei

Liu³

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…We included eight studies (four randomized controlled trials and four observational studies) for qualitative synthesis and meta‐analysis (Figure 1). We included 699 cases (eyes) from eight studies 10‐16 …”

Section: Resultsmentioning

confidence: 99%

Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta‐analysis

Pranata

Vania

2020

J Evidence Based Medicine

View full text Add to dashboard Cite

Objectives:To evaluate the latest evidence concerning the efficacy of conbercept on vitrectomy for proliferative diabetic retinopathy (PDR) and its efficacy compared to control and other antivascular endothelial growth factor. Methods:We performed a systematic literature search on topics that assess the role of conbercept in patients undergoing vitrectomy for PDR from inception to November 2019, using PubMed, EuropePMC, Cochrane Central Database, ProQuest, ScienceDirect, and Clinicaltrials.gov. Two researchers independently searched literature, extracted data, and evaluated the risk of bias. RevMan 5.3 and StataMP 16 software were used to perform data analysis. Results: There were 699 cases (eyes) from eight studies. Baseline best-corrected visual acuity (BCVA) was better in the control group compared to conbercept group (mean difference [MD] = 0.13, I 2 = 0%). A greater BCVA improvement was observed in the conbercept group after 1-month (MD = -0.27, I 2 = 1%), 3-month (MD = -0.28, I 2 = 0%), and 6-month (MD = -0.20, I 2 = 78%) follow-up. The need for endodiathermy (odds ratio [OR] = 0.20, I 2 = 0%) and silicone oil tamponade use (OR = 0.59, I 2 = 72%) and intraoperative bleeding (OR = 0.11, I 2 = 33%) was lower in conbercept group. Postoperative early (OR = 0.22, I 2 = 0%) and late (OR = 0.47, I 2 = 0%) vitreous hemorrhage was lower in conbercept group. There was no significant difference in BCVA improvement and intraoperative outcome between conbercept and ranibizumab. Conclusions: Intravitreal conbercept was associated with a more significant BCVA improvement, better intraoperative outcome, and less postoperative vitreous hemorrhage compared to no conbercept. K E Y W O R D S conbercept, intravitreal, proliferative diabetic retinopathy, vitrectomy 1 116wileyonlinelibrary.com/journal/jebm J Evid Based Med. 2020;13:116-124.

show abstract

“…On the other hand, some studies reported different outcomes. Lu et al found that eyes treated with preoperative IVC had better visual outcomes than IVR for severe PDR [ 30 ]. One possible explanation for this inconsistency was the different sample sizes and inclusion criteria.…”

Section: Discussionmentioning

confidence: 99%

Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial

Guo

Zhou

et al. 2022

Eye and Vis

View full text Add to dashboard Cite

Background To compare the efficacy and safety of preoperative intravitreal injections of ranibizumab and conbercept in Chinese proliferative diabetic retinopathy (PDR) patients. Methods This prospective randomized controlled trial enrolled 90 eyes of 80 patients with PDR. Forty-four eyes of 40 patients that received intravitreal ranibizumab (IVR) injections (0.5 mg/0.05 mL) before vitreous surgeries were assigned to the IVR group. Forty-six eyes of 40 patients that received intravitreal conbercept (IVC) injections (0.5 mg/0.05 mL) before vitreous surgeries were assigned to the IVC group. Intraoperative and postoperative indices were assessed for further comparison between the two groups. Results There were no statistically significant differences in all surgery indices, including intraoperative indices (surgery time, P = 0.225; intraoperative bleeding, P = 0.808; endodiathermy use, P = 0.693; incidence of iatrogenic retinal breaks, P = 0.740; relaxing retinotomy, P = 0.682; retinal reattachment, P = 0.682 and silicone oil tamponade, P = 0.814) and postoperative indices (postoperative vitreous hemorrhage (VH), P = 0.808; neovascular glaucoma (NVG), P = 0.964; recurrent retinal detachment, P = 0.531; postoperative fibrovascular proliferation progression, P = 0.682 and reoperation, P = 0.955) between the two groups. There were no statistically significant differences in best-corrected visual acuity (BCVA) at each follow-up visit (P = 0.939, 0.669, 0.741 and 0.717, respectively) or in central retinal thickness (CRT) (P = 0.976, 0.699, 0.551 and 0.686, respectively). As for safety profile, both groups had no ocular or system adverse events during the observation period. Conclusions IVR and IVC as a pretreatment of vitrectomy had similar efficacy and safety profile for Chinese PDR patients. Trial registration: Registered at ClinicalTrials.gov (NCT05414149).

show abstract

Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy

Cited by 10 publications

References 29 publications

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta‐analysis

Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial

Contact Info

Product

Resources

About